Specifically, only wet AMD could be therapeutically managed through costly and invasive treatments, such as the anti-VEGF intravitreal injections, which can be ineffective in about 15% of patients (Krebs et al., 2013). The gene discussed is VEGFA; the disease is wet macular degeneration.